SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549


FORM 8-K

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934


Date of Report (Date of earliest event reported):  May 6, 2003

 

 

Anika Therapeutics, Inc.

(Exact Name of Registrant as Specified in Its Charter)

 

 

Massachusetts

 

000-21326

 

04-3145961

(State or Other Jurisdiction of
Incorporation or Organization)

 

(Commission file Number)

 

(I.R.S. Employer Identification No.)

 

 

 

 

 

160 New Boston Street, Woburn, Massachusetts

 

01801

(Address of Principal Executive Offices)

 

(Zip Code)

 


 

Registrant’s Telephone Number, Including Area Code: (781) 932-6616

 

 



 

ITEM 7:                            FINANCIAL STATEMTENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.

 

(c)          Exhibits

 

Exhibit 99.1 — Press Release of Anika Therapeutics, Inc. dated May 6, 2003.

 

ITEM 9:                            REGULATION FD DISCLOSURE.

 

This Form 8-K is being furnished to report information pursuant to Item 12 - Results of Operations and Financial Conditions in accordance with the interim guidance provided by the SEC pursuant to SEC Release No. 33-8216 and 34-47583.  On May 6, 2003, Anika Therapeutics, Inc. issued a press release (“Press Release”) announcing its financial results for the first quarter of 2003.  A copy of the Press Release is attached as Exhibit 99.1 to this Current Report and is incorporated herein by reference.

 

 

2



 

SIGNATURES

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized in Woburn, Massachusetts on May 6, 2003.

 

 

Anika Therapeutics, Inc.

 

 

 

May 6, 2003

By:

/s/  Charles H. Sherwood

 

 

Charles H. Sherwood, Ph.D.
Chief Executive Officer and President

 

 

3



 

Exhibit Index

 

Exhibit No.

 

Description

99.1

 

Press Release of Anika Therapeutics, Inc. dated May 6, 2003

 

 

4